Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor

  • STATUS
    Recruiting
  • End date
    Dec 23, 2021
  • participants needed
    363
  • sponsor
    OSE Immunotherapeutics
Updated on 14 March 2021
Investigator
Bérangère Vasseur, MD
Primary Contact
CHU Montpellier (1.9 mi away) Contact
+176 other location
serum bilirubin level
metastasis
pemetrexed
neutrophil count
brain metastases
docetaxel
cancer chemotherapy
alopecia
platinum-based chemotherapy
stage iv non-small cell lung cancer
lung carcinoma
secondary malignant neoplasm of liver

Summary

The aim of this study is to determine if the Investigational Medicinal Product Tedopi (OSE2101) is more effective than standard treatment in treating patients with stage IIIB NSCLC unsuitable for radiotherapy or metastatic NSCLC in second- or third-line treatment after failure of immune checkpoint-inhibitor regimens.

Details
Condition Non-Small Cell Lung Cancer, nsclc
Treatment docetaxel, Pemetrexed, OSE2101
Clinical Study IdentifierNCT02654587
SponsorOSE Immunotherapeutics
Last Modified on14 March 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note